Treatment of AML: Resurrection for gemtuzumab ozogamicin?

The Lancet

Volumn 379, Issue 9825, 2012, Pages 1468-1469

  Estey, Elihu ^a,b  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD33 ANTIGEN; CYTARABINE; DAUNORUBICIN; GEMTUZUMAB OZOGAMICIN;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER REGRESSION; CANCER RELAPSE; COMBINATION CHEMOTHERAPY; HUMAN; MONOTHERAPY; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84859903057     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)60534-0     Document Type: Note

References (11)

1. Castaigne S, Pautas C, Terré C, et al, for the Acute Leukemia French Association. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 2012; published online April 5. DOI:10.1016/S0140-6736(12)60485-1.
2. Burnett A, Wetzler M, Loweneberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol 2011; 29: 487-94.
3. Lowenberg B, Ossenkoppele G, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009; 361: 1235-48.
4. Burnett AK, Hills RK, Hunter AE, et al. The addition of gemtuzumab ozogamicin to intensive chemotherapy in older patients with AML produces a significant improvement in overall survival: results of the UK NCRI AML16 randomized trial. Blood 2011; 118: abstract 582.
5. Walter RB, Appelbaum FR, Estey EH, Bernstein ID. Acute myeloid leukemia stem cells and CD33-targeted therapy. Blood 2012; published online Jan 27. DOI:10.1182/blood-2011-11-325050.
6. Estey EH, Giles FJ, Beran M, et al. Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood 2002; 99: 4222-24.
7. Larson RA, Sievers EL, Stadtmauer EA, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 2005; 104: 1442-52.
8. Walter R, Kantarjian H, Huang X, et al. Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and MD Anderson Cancer Center study. J Clin Oncol 2010; 28: 1766-71.
9. Walter R, Gooley T, Wood B, et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol 2011; 29: 1190-97.
10. Petersdorf S, Kopecky K, Stuart RK, et al. Preliminary results of Southwest Oncology Group Study S0106: an international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia. Blood 2009; 114: abstract 790.
11. Burnett AK, Hills RK, Milligan D, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol 2010; 29: 369-77.